JG
ALLO icon

Jefferies Group’s Allogene Therapeutics ALLO Stock Holding History

Jefferies Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,000
Closed -$409K – 2531
2019
Q3 		$409K Sell
15,000
-13,000
-46% -$370K ﹤0.01% 1991
2019
Q2 		$752K Buy
+28,000
New +$780K 0.01% 1452

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Jefferies Group's ALLO Position: Q4 2019 in Review

Jefferies Group sold out of Allogene Therapeutics (ALLO) in Q4 2019, closing a stake of 15,000 shares — an estimated $409K sold.

Jefferies Group first reported a position in ALLO in Q2 2019 and held it in 2 quarters. The position peaked at $752K in Q2 2019. 116 funds tracked by Wall St. Rank hold ALLO as of Q4 2019.

  • Jefferies Group reported no remaining Allogene Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 15,000 Allogene Therapeutics shares in Q4 2019, an estimated $409K.
  • Jefferies Group first reported a position in Allogene Therapeutics in Q2 2019 and held it in 2 quarters.
  • Jefferies Group's Allogene Therapeutics position peaked at $752K in Q2 2019.
  • 116 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.